Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.42 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21509270 | 0.98 | CYP1A2 (0.48) | CYP1A2CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL13333879 | 0.98 | CYP1A2 (0.48) | CYP1A2CHRNB2CHRNA5CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL4062254 | 0.94 | CHRNB2 (0.46) | CHRNB2CHRNA5CHRNA7CHRNA4FFAR1 | |
| Hydrochloric Acid SCHEMBL21801329 | 0.94 | CHRNB2 (0.46) | CHRNB2CHRNA5CHRNA7CHRNA4FFAR1 | |
| Hydrochloric Acid SCHEMBL336873 | 0.94 | CHRNB2 (0.46) | CHRNB2CHRNA5CHRNA7CHRNA4FFAR1 | |
| SCHEMBL8198672 | 0.92 | CHRNB2 (0.47) | CYP1A2CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL13740779 | 0.92 | CHRNB2 (0.47) | CYP1A2CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL14077882 | 0.92 | CHRNB2 (0.47) | CYP1A2CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL27000151 | 0.84 | — | — | |
| SCHEMBL19343119 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636368-B2 | Ionizable lipids for nucleic acid delivery | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2026-05-26 | — | — | US | disclosed |
| US-20260078085-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-12503432-B2 | Ionizable lipids for nucleic acid delivery | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-12-23 | — | — | US | disclosed |
| EP-4630406-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121046-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| EP-3986866-B1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | PREC NANOSYSTEMS ULC (CA) | 2023-12-20 | — | — | EP | disclosed |
| US-20220396548-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2022-12-15 | — | — | US | disclosed |
| US-20220378917-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2022-12-01 | — | — | US | disclosed |
| CN-114746401-A | Ionizable lipids for nucleic acid delivery | 精密纳米系统有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3990441-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | Precision Nanosystems Inc (CA) | 2022-05-04 | — | — | EP | disclosed |
| EP-3986866-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | Precision Nanosystems Inc (CA) | 2022-04-27 | — | — | EP | disclosed |
| WO-2021000041-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | Precision Nanosystems Inc. (CA) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020252589-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | Precision Nanosystems Inc. (CA) | 2020-12-24 | — | — | WO | disclosed |
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-4971958-A | CALCIUM METABOLISM | BOEHRINGER MANNHEIM GMBH (DE) | 1990-11-20 | — | — | US | disclosed |
| US-4162322-A | ANTISECRETORY | SCIENCE UNION ET CIE, SOCIETE FRANCAISE DE RECHERCHE MED. (FR) | 1979-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CHRNA7 4746/4885OPRD1 3442/4885CYP1A2 3836/4885 |
| US-20220396548-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | RNASEH1, NSUN3, SLC67A1 | CHRNA7 3543/4885OPRD1 3423/4885CYP1A2 4833/4885 |
| US-12636368-B2 | Ionizable lipids for nucleic acid delivery | NSUN2, NSUN3, RNMT | CHRNA7 1972/4885OPRD1 177/4885CYP1A2 4574/4885 |
| US-20260078085-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | NSUN2, NSUN3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CHRNA7 2360/4885OPRD1 169/4885CYP1A2 4654/4885 |
| US-12503432-B2 | Ionizable lipids for nucleic acid delivery | RNASEH1, NSUN3, SLC67A1 | CHRNA7 3543/4885OPRD1 3423/4885CYP1A2 4833/4885 |
| US-20220378917-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | SLC7A1, CD4, NSUN3 | CHRNA7 3621/4885OPRD1 3294/4885CYP1A2 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.